Skip to content

Tuesday, 17 November 2026

African Startup Intelligence

    CONFIRMED CLOSURE · ◐ Medium

    54gene

    Genomics company that built a biobank of African DNA samples and became one of Nigeria's largest COVID testing providers. Raised about $45M, cut staff in 2022 and began winding down in July 2023.

    Wind-down began in July 2023 and assets, including the biobank, were offered for sale. In July 2025 the founder petitioned a Lagos court; it blocked a sale of assets. TechCabal reported on 1 Aug 2025 that the case awaited judgment. This is an operating closure, not a legal finding.

    Status evidence · 2 news sources on the wind-down, one on the record by the last CEO [S1, S2]

    Facts

    Headquarters
    Lagos, Nigeria
    Sector
    Health · Genomics and diagnostics
    Model
    B2B
    Last stage
    Series B
    Operated
    2019 to Jul 2023
    Time operating
    Unknown
    Disclosed capital
    $45.0m
    Last verified
    Not yet verified

    Named investors: Adjuvant Capital, Cathay AfricInvest Innovation Fund, Y Combinator, KdT Ventures, Endeavor Catalyst, Ingressive Capital, Future Africa, Microtraction

    What the public record says

    • Demand · [S2]

      Problems began in 2022, after the COVID-19 vaccine became widely available and a move into advanced molecular diagnostics failed. Revenue fell and the company had to raise money to survive.

      Said by: Dr Abasi Ene-Obong, founder, in a July 2025 court petition as reported by TechCabal; Adjuvant Capital declined to comment on the specifics and Cathay AfricInvest did not respond · TechCabal: Nigerian court blocks sale of 54gene's assets, as founder claims investor wrongdoing

    • Follow-on financing · [S2]

      He says that after COVID testing revenue dropped, investors insisted on a $100M Series C in April 2022, and that within a month it was clear the round could not be raised. He also says the board blocked funding he had lined up.

      Said by: Dr Abasi Ene-Obong, in the same petition as reported by TechCabal; his allegations against the investors are unproven · TechCabal: Nigerian court blocks sale of 54gene's assets, as founder claims investor wrongdoing

    • Unit economics · [S1]

      After branching into diagnostics through Seven River Labs in 2021, the company spent heavily on collection centres and equipment. Another report cited by TechCabal said the expected returns did not materialise. Two sources said COVID testing brought in at least $20M in revenue.

      Said by: People familiar with the business, quoted by TechCabal on 27 September 2023 · TechCabal: Exclusive: After raising $45m in two years, 54gene is shutting down

    • Follow-on financing · [S1]

      "Unfortunately, the company could not continue to operate financially, and it began to wind down in July."

      Said by: Ron Chiarello, then CEO, to TechCabal, 27 September 2023 · TechCabal: Exclusive: After raising $45m in two years, 54gene is shutting down

    • Team changes · [S3]

      In August 2022 the company cut 95 staff, mostly contract workers on COVID testing. In September a co-founder left. In October 2022 the founder stepped down as CEO and over 100 more staff (55% of those remaining) were laid off.

      Said by: TechCrunch, 28 October 2022, from the company's own confirmations · TechCrunch: 54gene valuation slashed by over $100M amid job cuts and CEO exit

    Factors are what a named source said. They are not ASI’s conclusion, and capital raised is not a measure of losses.

    Sources

    1. [S1]TechCabal: Exclusive: After raising $45m in two years, 54gene is shutting downNews report · 27 Sep 2023
    2. [S2]TechCabal: Nigerian court blocks sale of 54gene's assets, as founder claims investor wrongdoingNews report · 01 Aug 2025
    3. [S3]TechCrunch: 54gene valuation slashed by over $100M amid job cuts and CEO exitNews report · 28 Oct 2022
    4. [S4]TechCrunch: African genomics startup 54gene raises $15M led by Adjuvant CapitalNews report · 14 Apr 2020

    History of this record

    1. Record created. Total raised is the reported $45M (rounds add to $44.5M). The founder's claims about investors are his; Adjuvant declined to comment and Cathay did not respond. They are not stated as fact.

    The record is open to evidence and response.

    If something here is wrong, or you were part of this company and want to add your account, tell us. Every material change is logged above.

    Correct the record

    Request a correction

    Tell us which field is wrong and what shows it. A company or founder named in a record may also send a response. ASI invites one before publishing and logs every material revision.

    We use your name and email only to reply about this request. They are never published.

    Right of reply

    Request a right of reply

    Founders and authorised representatives can ask to have a public response published beside the record. Say who you are and what you want to add. Private submissions are not published without permission, and no personal contact data is displayed.

    We use your name and email only to reply about this request. They are never published.

    Read the publication standards